Euro-celtique S.a.

Purdue Pharma L.p.

Hassan Mohammad

Malcolm Walden

Geoffrey Gerard Hayes

Helen Kathleen Danagher

Derek Allan Prater

Jonathon Oliver Whitehouse

Harjit Tamber

Stewart Thomas Leslie

Ronald Brown Miller

Thinnayam Naganathan Krishnamurthy

Ricardo Alberto Vargas Rincon

Trevor John Knott

Steve Whitelock

Sandra Therese Antoinette Malkowska

Gerhard Josef Heun

Vincenzo Martinelli

Kevin John Smith

Alexander Oksche

Vanessa Addison

Bernard Kennedy

Will Heath

Jonothon Oliver Whitehouse

The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.

Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome

The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human beings.

Manufacturing of active-free granules and tablets comprising the same

The present invention relates to prolonged release pharmaceutical dosage forms, the manufacture thereof as well as their use for administration to human being.

Combination of active loaded granules with additional actives

The present invention pertains to oral immediate release pharmaceutical compositions suitable for treating patients suffering from pain comprising oxycodone and naloxone or their pharmaceutically acceptable salts.

Immediate release pharmaceutical compositions comprising oxycodone and naloxone

The present invention provides a dosage form, particularly a tamper resistant dosage form, comprising: melt-extruded particulates comprising a drug; and a matrix; wherein said melt-extruded particulates are present as a discontinuous phase in said matrix.

Tamper resistant dosage form comprising a matrix and melt-extruded particulates comprising a drug

The present invention relates to a composition, comprising (i) a matrix made of polymeric nanofibers, and (ii) an opioid agonist within the matrix.

Opioid composition for treating skin lesions

Pharmaceutical compositions comprising hydromorphone and naloxone

The invention relates to a process for preparing a controlled release pharmaceutical extrudate using a melt extruder,

Extrusion

Extrusion of a mix containing a pharmaceutically active agent can be achieved using a plasticizing excipient in an amount sufficient to act as plasticizer and also act as lubricant, thereby avoiding the need for inclusion of a lubricant. The invention provides multiparticulates with controlled release properties, substantially free of lubricant. The present invention is preferably directed to extruded multiparticulates containing an opioid such as oxycodone, an ammonium methacrylate copolymer such as Eudragit&#xae; RSPO, a plasticizing excipient such as preferably stearyl alcohol and a water permeability modifier such as preferably Eudragit&#xae; RLPO. The obtained multiparticulates show a release rate profile which is pH-independent.

Multiparticulates

According to the invention glyceryl monostearate and a polymeric binder are employed as a spheronising aid in the manufacture of pharmaceutical spheroids containing no or substantially no microcrystalline cellulose. The spheroids can contain one or more therapeutically active agent which undergoes no or substantially no degradation when stored under accelerated temperature and humidity conditions. A coating may be applied to the spheroids; when present, the coating is preferably a controlled release coating.

Pharmaceutical spheroids

A neutral poly(ethyl acrylate, methyl methacrylate) copolymer is employed as a carrier in the manufacture of pharmaceutical formulations containing an active ingredient. The formulations are preferably made by melt extrusion, and can have rubbery characteristics and can exhibit tamper resistance.

Particulates

According to the present invention there is provided a pharmaceutical product for retention in the stomach. The product is produced by extrusion. The use of extrusion enables the product to take many useful forms. The product may comprise a sheet of hydratable polymer, the hydrated sheet being of a size which will not pass out of the stomach, for example a shaped sheet or a roll. The product may also comprise a scaled hollow tubular extrudate, for example a tube scaled at both ends. The product may comprise a filled capsule.

Gastroretentive drug delivery system comprising an extruded hydratable polymer

A solid, oral controlled release pharmaceutical dosage form has a water-soluble active ingredient dispersed in a matrix and releases the active ingredient at such a rate upon administration that the median tmax is 2.5 to 6 hours and the ratio of mean Cmax to mean plasma level of the active ingredient at 24 hours is in the range of 1.5 to 3.5.

Growing community of inventors

Cambridge, United Kingdom

Hassan Mohammad